{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:35:55Z","timestamp":1794656155003,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974098"],"award-info":[{"award-number":["81974098"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170784"],"award-info":[{"award-number":["82170784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Benign prostatic hyperplasia (BPH) is an age-related condition in men with a poorly defined etiology. Chronic inflammation is increasingly recognized as a key contributor to BPH progression; however, the underlying mechanisms remain incompletely understood. This study aimed to elucidate the role of a TNF-\u03b1-induced inflammatory microenvironment in regulating BPH progression. We demonstrated that TNF-\u03b1 levels were significantly elevated in patients with BPH and positively correlated with key clinical characteristics. In vitro, TNF-\u03b1 promoted the proliferation of prostatic cells. Mechanistically, TNF-\u03b1 induced the overexpression of SOX4, which subsequently activated the TGF-\u03b2\/Smad2\/3 signaling axis, thereby enhancing cellular proliferation, promoting epithelial-mesenchymal transition (EMT), and exacerbating fibrosis. Importantly, metformin (Met) treatment reduced the expression levels of relevant inflammatory cytokines in the serum of BPH rats. Further analysis confirmed that Met inhibited the TGF-\u03b2\/Smad2\/3 signaling pathway by downregulating the expression of SOX4, thus suppressing cell proliferation, reversing EMT, alleviating fibrosis, and ultimately exerting anti-BPH effects. Collectively, our findings suggest that TNF-\u03b1 promotes BPH progression via activation of the SOX4\/TGF-\u03b2\/Smad2\/3 axis, while Met exerts therapeutic effects by targeting this pathway. These results highlight SOX4 as a potential therapeutic target for BPH and support the clinical potential of Met in BPH management.<\/jats:p>","DOI":"10.1038\/s41419-025-07783-x","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:00:54Z","timestamp":1751353254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["TNF-\u03b1 modulates cell proliferation via SOX4\/TGF-\u03b2\/Smad signaling in benign prostatic hyperplasia"],"prefix":"10.1038","volume":"16","author":[{"given":"Jinze","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-8196","authenticated-orcid":false,"given":"Asmaa","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7597-6241","authenticated-orcid":false,"given":"Liangren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"7783_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.15229","volume":"127","author":"CM Devlin","year":"2021","unstructured":"Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia - what do we know? BJU Int. 2021;127:389\u201399.","journal-title":"BJU Int"},{"key":"7783_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.05.021","volume":"121","author":"GP Hoke","year":"2008","unstructured":"Hoke GP, McWilliams GW. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med. 2008;121:S3\u201310.","journal-title":"Am J Med"},{"key":"7783_CR3","first-page":"1","volume":"22","author":"C Vuichoud","year":"2015","unstructured":"Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22:1\u20136.","journal-title":"Can J Urol"},{"key":"7783_CR4","first-page":"1204","volume":"22","author":"M DerSarkissian","year":"2016","unstructured":"DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF. Comparing clinical and economic outcomes associated with early initiation of combination therapy of an alpha blocker and dutasteride or finasteride in men with benign prostatic hyperplasia in the United States. J Manag Care Spec Pharm. 2016;22:1204\u201314.","journal-title":"J Manag Care Spec Pharm"},{"key":"7783_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.envint.2019.02.006","volume":"126","author":"WH Chang","year":"2019","unstructured":"Chang WH, Tsai YS, Wang JY, Chen HL, Yang WH, Lee CC. Sex hormones and oxidative stress mediated phthalate-induced effects in prostatic enlargement. Environ Int. 2019;126:184\u201392.","journal-title":"Environ Int"},{"key":"7783_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.exger.2004.12.008","volume":"40","author":"G Untergasser","year":"2005","unstructured":"Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005;40:121\u20138.","journal-title":"Exp Gerontol"},{"key":"7783_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40618-014-0051-3","volume":"37","author":"L Vignozzi","year":"2014","unstructured":"Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease?. J Endocrinol Investig. 2014;37:313\u201322.","journal-title":"J Endocrinol Investig"},{"key":"7783_CR8","doi-asserted-by":"publisher","first-page":"103511","DOI":"10.1016\/j.autrev.2023.103511","volume":"23","author":"V Liedtke","year":"2024","unstructured":"Liedtke V, St\u00f6ckle M, Junker K, Roggenbuck D. Benign prostatic hyperplasia - a novel autoimmune disease with a potential therapy consequence?. Autoimmun Rev. 2024;23:103511.","journal-title":"Autoimmun Rev"},{"key":"7783_CR9","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/pros.21027","volume":"69","author":"G Robert","year":"2009","unstructured":"Robert G, Descazeaud A, Nicola\u00efew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients\u2019 immunohistochemical analysis. Prostate. 2009;69:1774\u201380.","journal-title":"Prostate"},{"key":"7783_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.acuro.2010.02.028","volume":"34","author":"F Manzarbeitia","year":"2010","unstructured":"Manzarbeitia F, Vela Navarrete R, Fernandez-Acenero MJ. Early histopathological aspects of benign prostatic hyperplasia: myxoid-inflammatory nodules]. Actas Urol Esp. 2010;34:549\u201354.","journal-title":"Actas Urol Esp"},{"key":"7783_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2605.2009.00972.x","volume":"33","author":"B Fibbi","year":"2010","unstructured":"Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010;33:475\u201388.","journal-title":"Int J Androl"},{"key":"7783_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4103\/aja.aja_100_18","volume":"21","author":"Y Fan","year":"2019","unstructured":"Fan Y, Yang L, Wei Q, Ding Y, Tang Z, Tan P, et al. Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells. Asian J Androl. 2019;21:393\u20139.","journal-title":"Asian J Androl"},{"key":"7783_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/13685538.2022.2050360","volume":"25","author":"J Li","year":"2022","unstructured":"Li J, Li Y, Cao D, Huang Y, Peng L, Meng C, et al. The association between histological prostatitis and benign prostatic hyperplasia: a single-center retrospective study. Aging Male. 2022;25:88\u201393.","journal-title":"Aging Male"},{"key":"7783_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bju.12118","volume":"112","author":"G Gandaglia","year":"2013","unstructured":"Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432\u201341.","journal-title":"BJU Int"},{"key":"7783_CR15","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/jcm12051821","volume":"12","author":"X Naiyila","year":"2023","unstructured":"Naiyila X, Li J, Huang Y, Chen B, Zhu M, Li J, et al. A novel insight into the immune-related interaction of inflammatory cytokines in benign prostatic hyperplasia. J Clin Med. 2023;12:1821.","journal-title":"J Clin Med"},{"key":"7783_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00011-013-0633-0","volume":"62","author":"H Zelov\u00e1","year":"2013","unstructured":"Zelov\u00e1 H, Ho\u0161ek J. TNF-\u03b1 signalling and inflammation: interactions between old acquaintances. Inflamm Res. 2013;62:641\u201351.","journal-title":"Inflamm Res"},{"key":"7783_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","volume":"25","author":"LM Sedger","year":"2014","unstructured":"Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;25:453\u201372.","journal-title":"Cytokine Growth Factor Rev"},{"key":"7783_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.4103\/aja2021114","volume":"24","author":"Y Tong","year":"2022","unstructured":"Tong Y, Guo YJ, Zhang Q, Bi HX, Kai K, Zhou RY. Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-\u03b1 from M1 macrophages and promotes proliferation of prostate stromal cells. Asian J Androl. 2022;24:513\u201320.","journal-title":"Asian J Androl"},{"key":"7783_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29719-1","volume":"13","author":"RE Vickman","year":"2022","unstructured":"Vickman RE, Aaron-Brooks L, Zhang R, Lanman NA, Lapin B, Gil V, et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nature Commun. 2022;13:2133.","journal-title":"Nature Commun"},{"key":"7783_CR20","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.1128\/MCB.02179-06","volume":"27","author":"D Sinner","year":"2007","unstructured":"Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, et al. Sox17 and Sox4 differentially regulate beta-catenin\/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007;27:7802\u201315.","journal-title":"Mol Cell Biol"},{"key":"7783_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2019.08.027","volume":"67","author":"CS Moreno","year":"2020","unstructured":"Moreno CS. SOX4: the unappreciated oncogene. Semin Cancer Biol. 2020;67:57\u201364.","journal-title":"Semin Cancer Biol"},{"key":"7783_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/sj.bjc.6604884","volume":"100","author":"CL Andersen","year":"2009","unstructured":"Andersen CL, Christensen LL, Thorsen K, Schepeler T, S\u00f8rensen FB, Verspaget HW, et al. Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer. 2009;100:511\u201323.","journal-title":"Br J Cancer"},{"key":"7783_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01568-2","volume":"20","author":"J Zhang","year":"2020","unstructured":"Zhang J, Xiao C, Feng Z, Gong Y, Sun B, Li Z, et al. SOX4 promotes the growth and metastasis of breast cancer. Cancer Cell Int. 2020;20:468.","journal-title":"Cancer Cell Int"},{"key":"7783_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/pcan.2013.25","volume":"16","author":"L Wang","year":"2013","unstructured":"Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, et al. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis. 2013;16:301\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7783_CR25","doi-asserted-by":"publisher","first-page":"111616","DOI":"10.1016\/j.exger.2021.111616","volume":"156","author":"X Ye","year":"2021","unstructured":"Ye X, Yin C, Huang X, Huang Y, Ding L, Jin M, et al. ROS\/TGF-\u03b2 signal mediated accumulation of SOX4 in OA-FLS promotes cell senescence. Exp Gerontol. 2021;156:111616.","journal-title":"Exp Gerontol"},{"key":"7783_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.40386","volume":"70","author":"P Bhattaram","year":"2018","unstructured":"Bhattaram P, Muschler G, Wixler V, Lefebvre V. Inflammatory cytokines stabilize SOXC transcription factors to mediate the transformation of fibroblast-like synoviocytes in arthritic disease. Arthritis Rheumatol. 2018;70:371\u201382.","journal-title":"Arthritis Rheumatol"},{"key":"7783_CR27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1161\/CIRCRESAHA.121.319540","volume":"130","author":"M Jia","year":"2022","unstructured":"Jia M, Li Q, Guo J, Shi W, Zhu L, Huang Y, et al. Deletion of BACH1 attenuates atherosclerosis by reducing endothelial inflammation. Circ Res. 2022;130:1038\u201355.","journal-title":"Circ Res"},{"key":"7783_CR28","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.4161\/cc.9.22.14048","volume":"9","author":"S Cuf\u00ed","year":"2010","unstructured":"Cuf\u00ed S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGF\u03b2-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle. 2010;9:4461\u20138.","journal-title":"Cell Cycle"},{"key":"7783_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11033-022-07954-5","volume":"50","author":"YY Feng","year":"2023","unstructured":"Feng YY, Wang Z, Pang H. Role of metformin in inflammation. Mol Biol Rep. 2023;50:789\u201398.","journal-title":"Mol Biol Rep"},{"key":"7783_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jare.2022.02.017","volume":"43","author":"CK Cheng","year":"2023","unstructured":"Cheng CK, Lin X, Pu Y, Tse JKY, Wang Y, Zhang CL, et al. SOX4 is a novel phenotypic regulator of endothelial cells in atherosclerosis revealed by single-cell analysis. J Adv Res. 2023;43:187\u2013203.","journal-title":"J Adv Res"},{"key":"7783_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep15639","volume":"5","author":"HH Mosli","year":"2015","unstructured":"Mosli HH, Esmat A, Atawia RT, Shoieb SM, Mosli HA, Abdel-Naim AB. Metformin attenuates testosterone-induced prostatic hyperplasia in rats: a pharmacological perspective. Sci Rep. 2015;5:15639.","journal-title":"Sci Rep"},{"key":"7783_CR32","doi-asserted-by":"publisher","first-page":"e96801","DOI":"10.1371\/journal.pone.0096801","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9:e96801.","journal-title":"PLoS ONE"},{"key":"7783_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.15229","volume":"127","author":"CM Devlin","year":"2021","unstructured":"Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia \u2013 what do we know?. BJU Int. 2021;127:389\u201399.","journal-title":"BJU Int"},{"key":"7783_CR34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.juro.2015.03.103","volume":"194","author":"KC Torkko","year":"2015","unstructured":"Torkko KC, Wilson RS, Smith EE, Kusek JW, van Bokhoven A, Lucia MS. Prostate biopsy markers of inflammation are associated with risk of clinical progression of benign prostatic hyperplasia: findings from the MTOPS study. J Urol. 2015;194:454\u201361.","journal-title":"J Urol"},{"key":"7783_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","volume":"214","author":"JR Bradley","year":"2008","unstructured":"Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149\u201360.","journal-title":"J Pathol"},{"key":"7783_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-082708-100732","volume":"27","author":"M Feldmann","year":"2009","unstructured":"Feldmann M. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol. 2009;27:1\u201327.","journal-title":"Annu Rev Immunol"},{"key":"7783_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2011.03.055","volume":"60","author":"C De Nunzio","year":"2011","unstructured":"De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schr\u00f6der F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60:106\u201317.","journal-title":"Eur Urol"},{"key":"7783_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0002-9440(10)61681-1","volume":"159","author":"D Giri","year":"2001","unstructured":"Giri D, Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol. 2001;159:139\u201347.","journal-title":"Am J Pathol"},{"key":"7783_CR39","doi-asserted-by":"publisher","first-page":"ra49","DOI":"10.1126\/scisignal.2000338","volume":"2","author":"TJ Jerde","year":"2009","unstructured":"Jerde TJ, Bushman W. IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia. Sci Signal. 2009;2:ra49.","journal-title":"Sci Signal"},{"key":"7783_CR40","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1124\/jpet.114.218693","volume":"351","author":"AM Hahn","year":"2014","unstructured":"Hahn AM, Myers JD, McFarland EK, Lee S, Jerde TJ. Interleukin-driven insulin-like growth factor promotes prostatic inflammatory hyperplasia. J Pharm Exp Ther. 2014;351:605\u201315.","journal-title":"J Pharm Exp Ther"},{"key":"7783_CR41","first-page":"1010","volume":"2","author":"E Shankar","year":"2015","unstructured":"Shankar E, Bhaskaran N, MacLennan GT, Liu G, Daneshgari F, Gupta S. Inflammatory signaling involved in high-fat diet induced prostate diseases. J Urol Res. 2015;2:1010.","journal-title":"J Urol Res"},{"key":"7783_CR42","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.3390\/ijms241310592","volume":"24","author":"LA Palafox-Mariscal","year":"2023","unstructured":"Palafox-Mariscal LA, Ortiz-Lazareno PC, Jave-Su\u00e1rez LF, Aguilar-Lemarroy A, Villase\u00f1or-Garc\u00eda MM, Cruz-Lozano JR, et al. Pentoxifylline inhibits TNF-\u03b1\/TGF-\u03b21-induced epithelial-mesenchymal transition via suppressing the NF-\u03baB pathway and SERPINE1 expression in CaSki cells. Int J Mol Sci. 2023;24:10592.","journal-title":"Int J Mol Sci"},{"key":"7783_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbrc.2015.09.121","volume":"467","author":"T Adachi","year":"2015","unstructured":"Adachi T, Arito M, Suematsu N, Kamijo-Ikemori A, Omoteyama K, Sato T, et al. Roles of layilin in TNF-\u03b1-induced epithelial-mesenchymal transformation of renal tubular epithelial cells. Biochem Biophys Res Commun. 2015;467:63\u201369.","journal-title":"Biochem Biophys Res Commun"},{"key":"7783_CR44","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/cas.14455","volume":"111","author":"Y Yoshimatsu","year":"2020","unstructured":"Yoshimatsu Y, Wakabayashi I, Kimuro S, Takahashi N, Takahashi K, Kobayashi M, et al. TNF-\u03b1 enhances TGF-\u03b2-induced endothelial-to-mesenchymal transition via TGF-\u03b2 signal augmentation. Cancer Sci. 2020;111:2385\u201399.","journal-title":"Cancer Sci"},{"key":"7783_CR45","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871\u201390.","journal-title":"Cell"},{"key":"7783_CR46","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028\u201340.","journal-title":"Nat Med"},{"key":"7783_CR47","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0002-9440(10)64282-4","volume":"162","author":"M Chilosi","year":"2003","unstructured":"Chilosi M, Poletti V, Zam\u00f2 A, Lestani M, Montagna L, Piccoli P, et al. Aberrant Wnt\/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 2003;162:1495\u2013502.","journal-title":"Am J Pathol"},{"key":"7783_CR48","doi-asserted-by":"publisher","first-page":"23337","DOI":"10.1074\/jbc.M700194200","volume":"282","author":"M Zeisberg","year":"2007","unstructured":"Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem. 2007;282:23337\u201347.","journal-title":"J Biol Chem"},{"key":"7783_CR49","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/nm888","volume":"9","author":"M Zeisberg","year":"2003","unstructured":"Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003;9:964\u20138.","journal-title":"Nat Med"},{"key":"7783_CR50","doi-asserted-by":"publisher","first-page":"e2304274","DOI":"10.1002\/advs.202304274","volume":"11","author":"D Lin","year":"2024","unstructured":"Lin D, Luo C, Wei P, Zhang A, Zhang M, Wu X, et al. YAP1 recognizes inflammatory and mechanical cues to exacerbate benign prostatic hyperplasia via promoting cell survival and fibrosis. Adv Sci. 2024;11:e2304274.","journal-title":"Adv Sci"},{"key":"7783_CR51","doi-asserted-by":"publisher","first-page":"9309","DOI":"10.1073\/pnas.0401994101","volume":"101","author":"DR Rhodes","year":"2004","unstructured":"Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA. 2004;101:9309\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7783_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000129","volume":"4","author":"K Yu","year":"2008","unstructured":"Yu K, Ganesan K, Tan LK, Laban M, Wu J, Zhao XD, et al. A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet. 2008;4:e1000129.","journal-title":"PLoS Genet"},{"key":"7783_CR53","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113\u201320.","journal-title":"Nat Genet"},{"key":"7783_CR54","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.semcancer.2019.06.008","volume":"67","author":"X Wu","year":"2020","unstructured":"Wu X, Xin Z, Zou Z, Lu C, Yu Z, Feng S, et al. SRY-related high-mobility-group box 4: Crucial regulators of the EMT in cancer. Semin Cancer Biol. 2020;67:114\u201321.","journal-title":"Semin Cancer Biol"},{"key":"7783_CR55","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.trecan.2017.06.002","volume":"3","author":"AR Louren\u00e7o","year":"2017","unstructured":"Louren\u00e7o AR, Coffer PJ. SOX4: joining the master regulators of epithelial-to-mesenchymal transition?. Trends Cancer. 2017;3:571\u201382.","journal-title":"Trends Cancer"},{"key":"7783_CR56","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1042\/CS20210476","volume":"135","author":"J Liu","year":"2021","unstructured":"Liu J, Liu D, Zhang X, Li Y, Fu X, He W, et al. NELL2 modulates cell proliferation and apoptosis via ERK pathway in the development of benign prostatic hyperplasia. Clin Sci. 2021;135:1591\u2013608.","journal-title":"Clin Sci"},{"key":"7783_CR57","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9 J. TGFbeta in cancer. Cell. 2008;134:215\u201330.","journal-title":"Cell"},{"key":"7783_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2853","volume":"10","author":"H Ikushima","year":"2010","unstructured":"Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415\u201324.","journal-title":"Nat Rev Cancer"},{"key":"7783_CR59","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1073\/pnas.0812666106","volume":"106","author":"P Alonso-Magdalena","year":"2009","unstructured":"Alonso-Magdalena P, Br\u00f6ssner C, Reiner A, Cheng G, Sugiyama N, Warner M, et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA. 2009;106:2859\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7783_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/09687688.2014.894211","volume":"31","author":"S Hu","year":"2014","unstructured":"Hu S, Yu W, Lv TJ, Chang CS, Li X, Jin J. Evidence of TGF-\u03b21 mediated epithelial-mesenchymal transition in immortalized benign prostatic hyperplasia cells. Mol Membr Biol. 2014;31:103\u201310.","journal-title":"Mol Membr Biol"},{"key":"7783_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10522-025-10226-x","volume":"26","author":"A Khan","year":"2025","unstructured":"Khan A, Alzahrani HA, Felemban SG, Algarni AS, Alenezi ABS, Kamal M, et al. Exploring TGF-\u03b2 signaling in benign prostatic hyperplasia: from cellular senescence to fibrosis and therapeutic implications. Biogerontology. 2025;26:79.","journal-title":"Biogerontology"},{"key":"7783_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01644-4","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Li J, Zhou L, Wang Z, Jin L, Cao J, et al. Aberrant activation of TGF-\u03b2\/ROCK1 enhances stemness during prostatic stromal hyperplasia. Cell Commun Signal. 2024;22:257.","journal-title":"Cell Commun Signal"},{"key":"7783_CR63","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.febslet.2012.02.037","volume":"586","author":"CH Heldin","year":"2012","unstructured":"Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGF\u03b2 in cancer. FEBS Lett. 2012;586:1959\u201370.","journal-title":"FEBS Lett"},{"key":"7783_CR64","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU Guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099\u2013109.","journal-title":"Eur Urol"},{"key":"7783_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211:11\u201319.","journal-title":"J Urol"},{"key":"7783_CR66","first-page":"5625","volume":"11","author":"MS Misirkic Marjanovic","year":"2021","unstructured":"Misirkic Marjanovic MS, Vucicevic LM, Despotovic AR, Stamenkovic MM, Janjetovic KD. Dual anticancer role of metformin: an old drug regulating AMPK dependent\/independent pathways in metabolic, oncogenic\/tumorsuppresing and immunity context. Am J Cancer Res. 2021;11:5625\u201343.","journal-title":"Am J Cancer Res"},{"key":"7783_CR67","doi-asserted-by":"publisher","first-page":"16931","DOI":"10.1007\/s00432-023-05391-w","volume":"149","author":"Z Wu","year":"2023","unstructured":"Wu Z, Wang W, Wei L, Zhu S. Current status and frontier tracking of clinical trials on Metformin for cancer treatment. J Cancer Res Clin Oncol. 2023;149:16931\u201346.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7783_CR68","doi-asserted-by":"publisher","first-page":"17010","DOI":"10.1038\/celldisc.2017.10","volume":"3","author":"P Shi","year":"2017","unstructured":"Shi P, Liu W, Tala, Wang H, Li F, Zhang H, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov. 2017;3:17010.","journal-title":"Cell Discov"},{"key":"7783_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41421-018-0033-2","volume":"4","author":"S Melnik","year":"2018","unstructured":"Melnik S, Dvornikov D, M\u00fcller-Decker K, Depner S, Stannek P, Meister M, et al. Cancer cell specific inhibition of Wnt\/\u03b2-catenin signaling by forced intracellular acidification. Cell Discov. 2018;4:37.","journal-title":"Cell Discov"},{"key":"7783_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173335","volume":"12","author":"Z Wang","year":"2017","unstructured":"Wang Z, Xiao X, Ge R, Li J, Johnson CW, Rassoulian C, et al. Metformin inhibits the proliferation of benign prostatic epithelial cells. PLoS ONE. 2017;12:e0173335.","journal-title":"PLoS ONE"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07783-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07783-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07783-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:06:32Z","timestamp":1751396792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07783-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7783"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07783-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}